Navigation Links
Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions

cial analysts to discuss this news release today at 8:30 a.m., EST. A simultaneous webcast of the call for interested investors and others may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections reflected in this press release. Risks and uncertainties include general industry conditions and competition; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov or on request from Johnson & Johnson or Conor Medsystems, LLC. Neither Johnson & Johnson nor Conor Medsystems undertakes to update any forward-looking statements as a result of new information or future events or developments.)

CONTACT: media, Christopher Allman, +1-305-586-6024; investor, LouiseMehrotra, +1-732-524-6491; Stan Panasewicz, +1-732-524-2524; LesleyFishman, +1-732-524-3922

Web site: '"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
(Date:5/19/2013)... Utah (PRWEB) May 19, 2013 ... on small business health insurance . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and the self-employed intrinsically know the value of ...
(Date:5/19/2013)... The report “Feed Additives Market by ... up to 2017” published by MarketsandMarkets, defines and segments ... forecasting of the global volume and revenue for the ... restraining factors for the global market with analysis of ... market is segmented and revenue is forecasted on the ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with ... increase the chance of a healthier smile. Laser gum ... not only removes diseased gum tissue in patients, but it ... dental implants. , LANAP uses a laser to ... help stimulate the healthy tissue as well as encourage new ...
(Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
(Date:5/19/2013)... Vedra Beach, Florida (PRWEB) May 19, 2013 ... value and market access, is pleased to unveil a ... trade show environment that provides a powerful array of ... to partners in the US and abroad. , HE-Xpo ... and will offer attendees the look and feel of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... Institute scientists, discovery of a cancer-causing gene the first ... how the panoramic view of genomics and the close-up perspective ... involved in cancer and which are mere bystanders. The findings ... Nature . "In the coming years, we can ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... finds , WEDNESDAY, June 24 (HealthDay News) -- Monitoring ... drugs to prevent osteoporosis is unnecessary and could be ... researchers analyzed data from a large randomized trial that ... used bisphosphonate) in more than 6,000 postmenopausal women with ...
... Furthering its mission to improve the quality of ... signed a cooperative agreement with nine countries belonging ... In a drive to strengthen capacities and certification ... from Cambodia, Laos, Myanmar, Singapore, Vietnam, Indonesia, Malaysia, ...
... ... Services , ... Francisco, CA (PRWEB) June 24, 2009 -- Today, Quantros announced the launch of a ... Quantros IT Consulting Services provides a cost-effective and reliable model for creating and supporting ...
... "Superfruit" Beverages Expand Beverages Holdings, Wholesome Offerings , , ... of the Sunny Delight Beverages Co., Veryfine Co. and The ... all the assets of Bossa Nova Beverage Group, Inc., a ... beverage category with its original acai juice . ...
Cached Medicine News:Health News:Study pinpoints novel cancer gene and biomarker 2Health News:Study pinpoints novel cancer gene and biomarker 3Health News:Study pinpoints novel cancer gene and biomarker 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Bone Therapy May Not Always Need Monitoring 2Health News:Goal of good quality medicines advanced by new USP agreement with 9 ASEAN countries 2Health News:Quantros Establishes IT Consulting Services Business Unit 2Health News:Quantros Establishes IT Consulting Services Business Unit 3Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 2Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: